logo
Investor Relations

Company Profile

With the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases.
Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

News Releases

Events & Presentations

Tue Oct 25th, 2022

LD Micro Main Event XV Webcast Link

Mon Sep 12th, 2022

24th Annual H.C. Wainwright Global Investment Conference Webcast Link

Financials & SEC Filings

Sign Up For Email Alerts

Receive updates straight into your inbox

Contact Us

Get in touch our team

Indaptus Therapeutics,
Three Columbus Circle, 15th Floor
New York, NY 10019.

Sign Up For Email Alerts

Receive updates straight into your inbox

Contact Us

Get in touch our team

Indaptus Therapeutics,
Three Columbus Circle, 15th Floor
New York, NY 10019.